摘要
脂肪肝是個愈來愈常見的問題，以往總是被人忽略，只認為這是個肥胖的代名詞，但是近年來發現脂肪肝中有一些患者是屬於非酒精性脂肪變性肝炎(Nonalcoholic steatohepatitis，NASH)，這類患者平均有7-17%最後會進展到肝硬化，因此喚起了醫界學者對它的注意。NASH好發在肥胖，高血脂症，糖尿病的患者。NASH的診斷主要是要靠肝臟切片才能與單純的脂肪肝做區分。其嚴重程度和生化檢查AST、ALT沒有相關。適當的飲食控制加上持續的運動計劃若能達到減重，確實可以改善ALT。除此之外，目前尚無特別有效的藥物可以改變其病程發展。有關NASH的病程發展及治療仍需更多研究才能夠明瞭。
並列摘要
Fatty liver is a common problem to many people. Most people overlook the fatty liver as they do to obesity. There are different subgroups in nonalcoholic fatty liver disease. The prognosis of simple steatosis is good. However, the prognosis of nonalcoholic steatohepatitis is different. 7% to 17% patients of nonalcoholic steatohepatitis may finally progress to liver cirrhosis. The risk groups of nonalcoholic steatohepatitis are the patients of obesity, hyperlipidemia, and diabetes mellitus. It is necessary to perform liver biopsy to differentiate simple steatosis from nonalcoholic steatohepatitis. There is no correlation between the severity of pathologic findings and the level of AST, ALT. There is no enough evidence to show which medicine can significantly change the natural course or prognosis of nonalcoholic steatohepatitis except weight reduction. It is necessary to do more studies to help us to understand the natural course and treatment of nonalcoholic steatohepatitis in the future.
延伸閱讀
- 林冠宏、陳杰（2023）。非酒精性脂肪肝疾病與代謝異常。臨床醫學月刊，91(2)，126-133。https://doi.org/10.6666/ClinMed.202302_91(2).0021
- 王舒儀（2019）。非酒精性脂肪肝疾病。彰基糖尿病友會刊，(13)，10-13。https://www.airitilibrary.com/Article/Detail?DocID=P20140804001-201912-201912130008-201912130008-10-13
- 蔡崇煌、黃素雲（2005）。非酒精性脂肪肝疾病。基層醫學，20(8)，182-186。https://doi.org/10.6965/PMCFM.200508.0182
- Shifflet, A., & Wu, G. Y. (2009). Non-alcoholic Steatohepatitis: An Overview. Journal of the Formosan Medical Association, 108(1), 4-12. https://www.airitilibrary.com/Article/Detail?DocID=09296646-200901-108-1-4-12-a
- (2010). Acute Hepatitis C. Statistics Of Communicable Diseases and Surveillance Report Republic China, (), 110-112. https://doi.org/10.30170/SCDSRRC.201012.0028